Search

Jan 15
SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs
He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel...

Jun 6, 2024
Biohaven's CEO recaps last week's R&D Day and walks us through the company's pipeline
From the NYSE, Vlad Coric covers programs including protein degradation, ADCs, myostatin inhibition, the ion channel programs, and...

Jan 7, 2024
Vlad Coric talks about the pipeline 'New Biohaven' has in motion after Pfizer's acquisition of its CGRPs
He discusses protein degradation, KV7 ion channel modulation, myostatin inhibition for obesity, and more.